secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0000950170-24-002304
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis reports Q4 revenue of $19.7M (+18% YoY); cash runway extended to Q1 2026
--------------------------------------------------------------------------------

- Preliminary Q4 revenue $19.7M, up 18% YoY from $16.7M; full-year revenue $73.5M, up 13%.
- Natera revenue in Q4 was $7.1M (vs $8.2M prior year); pharma/enterprise/other revenue $18.7M.
- Cash and short-term investments $114.0M; cash usage reduced to ~$54M in 2023 from $119M.
- Annual cost-cutting reduced expenses by ~$35M; cash runway extended to Q1 2026.
- CEO cites NeXT Personal Dx launch, Tempus partnership, and progress on clinical evidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024002304/0000950170-24-002304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024002304/psnl-20240105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer